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Conclusion: This study shows that both SCT and SCS have sub- 
stantial beneficial effects on HRQoL. By identifying patients 
socially isolated and by ensuring social integration of patients, 
future management of OA could lead to better health outcomes, 
especially in mental dimensions which have been consistently 
found to be impaired in OA. 
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RELATIONSHIP BETWEEN OARSI RESPONSE CRITERIA 
AND PATIENTS GLOBAL ASSESSMENT OF TREATMENT 
EFFICACY IN KNEE OSTEOARTHRITlS (OA) 
A KAHAN 1 PL LLEU 2 
~University Paris V AP-HP, Cochin Hospital, Paris, France, 
2 Boehringerlngeiheim, France 
~,im: The aim of this study was to assess the relationship 
between a recently published set of response criteria n knee OA 
and patients' global evaluation of efficacy. 
Methods: In knee OA patients (N=253) treated with Hylan G-F 20 
viscosupplementation, response rates according to patients' 
evaluation of efficacy (a "good" or "satisfactory" efficacy defin- 
ing "global responder" patients) were compared with OARSI 
response rates. OARSI knee intra-articular specific drug -propo- 
sition A and B- were studied (defining "OARSI A" or "OARSI B" 
responder patients). In these three populations of responders we 
described the absolute and relative mean changes over 9 months 
in WOMAC pain, WOMAC function and global assessment 
(patient's disease activity on a VAS). 
Results: OARSI A, OARSI B and global response rates were 
respectively 62.8%, 61.7% and 71.7%. Out of global responders, 
76.8% were OARSI A and 75.7% OARSI B responders. There 
were 87.5% and 87.9% global responders in OARSI A and B 
responders. 
Mean changes in the three responder populations were given 
below: 
OARSI A OARSI B Global 
responders 
Pain change 
- absolute (ram) - 35.6 + 14.8 
- relative (%) - 70.3 ± 20.6 
Function change 
- absolute (mm) -28.4 ± 15.7 
- relative (%) -62.7 ± 26.5 
Global assessment change 
- absolute (mm) - 41.7 + 21.4 
- relative (%) - 66.7 ± 30.0 
- 36.0 ± 14.7 - 29.6 ± 18.8 
- 70.6 ± 20.8 - 60.3 ± 32.3 
-29.0 ± 15.4 -23.3 ± 18.7 
-63.6 ± 25.4 -51.1 ± 40.6 
-41.9 ± 21.3 -35.6 ± 24.4 
- 67.0 ± 29.9 - 58.2 ± 39.5 
Conclusions: Higher mean changes in pain, function and global 
assessment are required to fulfill OARSI response criteria com- 
pared to patients' global response. Mean changes and response 
rates for knee intra-articular specific drug were similar whatever 
proposition A or B applied. 
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BONE EDEMA: DISSONANCE BETWEEN PAIN AND X-RAY 
OSTEOARTHRITIS 
MF Sowers. D Jamadar, L Lachance, D Capul, G Welch, 
C Hayes 
University of Michigan, Ann Arbor, MI, USA 
Bone marrow edema (BME) by magnetic resonance imaging 
(MRI) is a prominent finding of several pain syndromes. We 
hypothesized that subchondral BME coupled with information 
about the nature and location of focal cartilage defects would 
explain the conundrum of self-reported joint pain in the apparent 
absence of x-ray-defined knee osteoarthritis (OAK). A total of 
120 women grouped by self-reported pain and x-ray status (30 
per group) were identified from the Southeast Michigan Arthritis 
cohort of black-and white pre- and perimenopausal women 
(n=1053), aged 33-55, with weight bearing x-rays of both knees, 
self-reported knee joint pain and risk factors for OA. Definition of 
OAK was a Kellgren-Lawrence score of two or greater. 
Participants were evaluated using a 1.5 T (GE Sigma) scanner 
equipped with a knee surface coil. Sequences involved fast spin 
echo proton density with fat saturation sequences. Scoring for 
BME and cartilage defects were undertaken by two radiologists, 
blinded as to the x-ray OAK status and to group assignment. 
Group Pain x-ray OAK No BME No cartilage 
n=30/grp defect 
t No No 50% t7% 
2 No Yes 13% 0% 
3 Yes No 47% 20% 
4 Yes Yes 10% 0% 
Women with evidence of BME were 7 times more likely (95% 
C1=2.7,17.7) to be identified by x-ray as having OAK whereas the 
Odds ratio for BME and pain was 1.1 (95% Cl=0.5-2.5).The sum- 
mary BME in the worst knee did not account for self report of pain 
or account for the pain/x-ray OA incongruity in groups 2 and 3. 
BME is likely due to mild cellular injury, probably induced by 
micro-trauma. However, using a global measure of BME did not 
explain the dissonance between report of pain and x-ray findings. 
Further evaluation will be required to determine if comparison by 
compartment or severity is more explanatory of the dissonance. 
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THE AUSCAN OSTEOARTHRITIS (OA) HAND INDEX: USE IN 
THE EVALUATION OF HAND OA PATIENTS IN THE 
"ADVANTAGE" TRIAL 
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C. S. Skalky 3, N. Bellamy 2, 
1Merck and Co., Inc., West Point, PA 19486, USA 
2University of Queensland, Brisbane, Australia 
Method: A cohort of patients with OA of the hand was evaluated 
in a planned subgroup analysis, using AUSCAN OA Hand Index 
in a trial assessing the gastrointestinal (GI) tolerability of rofecox- 
ib (RO) and naproxen (NA) in the treatment of patients with knee, 
hip, hand, or spine OA over 12 weeks. Eligible patients were ran- 
domly assigned to treatment with RO 25 mg qd or NA 500 mg 
bid. GI tolerability, as defined by the incidence of discontinuations 
due to GI adverse experiences (AE), was the primary endpoint. 
OA efficacy was assessed by the Patient Global Assessment of 
Disease Status (PGADS), the AUSCAN OA Hand Index LK3.0S, 
and discontinuations due to lack of efficacy (LOE). 
Results: 5557 patients received RO (n=2785) or NA (n=2772). 
Baseline characteristics were similar between treatment groups. 
16.4% of patients (n=447 and 463; RO and NA respectively) 
patients identified the hand as their primary source of OA symp- 
toms and were required to complete the AUSCAN questionnaire, 
a categorical scale (Pain/Difficulty: 1=None to 5=Extreme) to 
assess three domains of hand OA (pain, stiffness, and physical 
function, comprised of 5, 1 and 9 questions, respectively). 
Patients were asked to select one pain item and one physical 
function item which they most hoped would improve. Also, all 
patients completed the PGADS, a 100 mm VAS (0=very well; 
100=very poor). 
Rotecoxib Naproxen P value 
PGADS change (mm) Hand* - 6.94 - 6.41 N S 
AUSCAN Pain Domain" - 0.28 - 0.31 N S 
AUSCAN Stiffness Domain* - 0.39 - 0.33 N S 
AUSCAN Function Domain" - 0.37 - 0.38 N S 
Discontinuations due to LOF 6.4% 6.3% N S 
GIAEDiscontinuations 5.9% 8.1% 0 . 0 0 5 
"Reported as mean change from baseline 
A preponderance of patients selected "When gripping objects 
with your hands" as the most important pain item (40%); where- 
as "Opening a new jar" was the most important physical function 
item (29%). 
Conclusion: In OA patients treated for 3 months, RO 25 mg qd 
exhibited superior Gt tolerability compared with NA 500 mg bid. 
In patients with hand OA, RO and NA provided similar efficacy 
whether assessed by PGADS or by the AUSCAN Hand Index, 
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OSTEOARTHRITIS OF THE ELBOW: AN ASYMPTOMATIC 
JOINT? 
L Shepstone ~, J Rogers 2, PAD~ 2 
University of EastAnglia, UK 2 University of Bristol, UK 
Aims: A review of the literature has revealed little clinical interest 
in OA of the elbow with its occurrence being reported as uncom- 
mon. However, clinical studies investigate exclusively sympto- 
matic joints and asymptomatic pathological involvement of joints 
will go unreported. Skeletal material provides an opportunity for 
studying the pathology of OA more fully. Eburnation and osteo- 
phytes, both pathologies associated with OA, are easily seen on 
skeletal remains; we have therefore aimed to estimate the preva- 
lence of OA pathologies of the elbow using a skeletal collection. 
Methods: 563 skeletons, excavated from one site in the UK, were 
used in this study. The radio-humeral (RHJ) and ulno-humeral 
(UHJ) joints were examined by one, experienced palaeopatholo- 
gist. The presence of eburnation and osteophytes were noted. 
Standard anthropological techniques were used to age ( <45 
years or >45 years) and sex the skeletons. 
Results: 48% of the sample were female and 37% were estimat- 
ed to be over 45 years at death. The prevalence of eburnation and 
osteophytes anywhere in the elbow was 4.2% and 16.5% 
respectively. Four individuals (17.4%) with eburnation did not 
have osteophytes. Eburnation was significantly more common in 
the RHJ than the UHJ (3.7% vs 0.9%; McNemar's o~ 2 10.7. 
p<0.001) yet osteophytes were significantly more common in the 
UHJ than the RHJ (13.6% vs 9.3%; McNemar's (j2 =10.4, p<0.00 
1). Osteophytes anywhere in the elbow were significantly more 
common in the older age group than younger (28.2% vs 9.7%, (u 2 
= 24.5, p<0.001) and in males than females (22.7% vs 9.8%, (~2 = 
16.1, p<0.001). Eburnation of the elbow was significantly more 
prevalent in the older age group than younger (1.5% vs 8.3%, e) ?- 
= 11.9, p<0.001) and more prevalent in males than females but not 
significantly so (5.4% vs 2.7%, (~2 = 2.4, p=0. 120). 
Conclusion: The prevalences estimated here are comparable 
with those of the hip and knee from other skeletal studies. These 
data, therefore, raise an important issue in our understanding of 
OA: the elbow is commonly affected pathologically - but by what 
mechanism is it spared symptomatically? 
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IN VITRO CHONDROPROTECTIVE ACTIVITY 
OF A NOVEL CLASS OF ANTHRAQUINONES 
M.Mian, A.Conte,* G.Ronca,** 
Eneo Research, Miami, USA *Department of Agricultural 
Sciences, University of Modena and Reggio Emilia, Italy 
**Department of Human and Environmental Sciences, University 
of Pisa, Italy 
Some anthraquinones (AQ) are used for the treatment of 
osteoarthritis (OA). We have synthesized some AQ from the par- 
ent compound anthraquinone 2,6-disulfonic acid (GR373). We 
have investigated the activity of anthraquinone 2,6-disulfonic acid 
(GR373); N,N-diethyl anthraquinone 2,6-disulfonamide(GR375) 
and 2,6-diphenetidin anthraquinone disulfonamide(GR377) on 
cathepsin B(cat-B), cathepsin L (cat-L), cyclooxygenase I (COX1) 
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and 2 (COX2), nitric oxide synthase (NOS) activities and on pro- 
teoglycan(PG)-release in cultured articular cartilage. 
Inhibition studies on cat-B and cat-L were carried out using vari- 
ous natural and synthetic substrates. COX1 and COX2 activities 
were determined in human blood after coagulation or after 24 h 
of LPS stimulation measuring TXB2 and PGE2 concentrations 
respectively. Human inducible NOS activity was measured by the 
formation of citrulUne from labeled arginine. 
Pieces of bovine articular cartilage were cultured in the presence 
or in the absence of IL-11]. PG content in both the medium and 
cartilage was assayed at various times. All the above tests have 
been carried out in the absence and in the presence of various 
concentrations of the AQ under investigation. 
The three tested AQ inhibited in a dose-dependent way both 
human cat-B and cat-L at micromolar concentrations. However 
the introduction of the above reported chemical groups on the 
parent compound GR373 greatly increases the inhibitory activity. 
The rank order of inhibition on both enzymes is 
GR377>GR375>GR373. Kinetic studies show that the inhibition 
is of the uncompetitive type. The tested AQ have no effect on 
COX1 while they inhibit COX2 and NOS at micromolar concen- 
trations. IL-Ib-induced PG release is significantly decreased by 
the tested AQ at micromolar concentrations, 
These results suggest that this novel class of AQ and in particu- 
lar the more active GR377 and GR375 have potential applica- 
tions in the treatment of OA since they may interfere with OA 
processes at different levels. 
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A RANDOMISED, DOUBLE-BLIND, COMPARATOR 
CLINICAL STUDY OF THE EFFICACY OF SODIUM 
PENTOSAN POLYSULFATE INJECTION AND CARPROFEN 
CAPSULES IN ARTHRITIC DOGS 
JG Smith ~, RL Harmon ~, L Brunnberg 2, V Gebski, D Cullis-Hill ~, 
2Freien University, Berlin, Germany; IBiopharm Australia, Sydney, 
Australia 
Aim and Methods: This study compared the efficacy and safety 
of two osteoarthritis treatments in a randomized, double-blind 
design utilizing skeletally mature dogs with osteoarthritis. The 
treatments were Cartrophen Vet (CVI, 100mg pentosan polysul- 
fate sodium/ml, 3mg/kg body weight, 4 x weekly injectlons sc; n 
= 53) and carprofen (NSAID, 4mg/kg body weight, 28 x daily cap- 
sules orally, n = 51) with appropriate placebos. Dogs were 
assessed by clinical examination at baseline and at Weeks 2, 3, 4 
and 8. 
Results: Analysis of the primary outcomes of lameness, pain and 
orthopaedic score, revealed that there was statistically significant 
improvement following treatment with CVI compared to treatment 
with NSAID at Week 8 (4 weeks after treatment had ceased) in 
orthopaedic score (p=0.013). Improvement following NSAID 
treatment relative to CVI treatment was statistically significant for 
lameness at Week 2 (p.<0.001), pain at Week 2 (p=0.023) and 
Week 3 (p<0.001) and orthopaedic score at Week 2 (p=0.041). The 
statistically significant difference at Week 2 for lameness in favor 
of NSAID was diminished by Week 8 with CVl the more favorable 
treatment (p=0.129). According to the primary outcome veterinar- 
ians' impression of the overall response to treatment, both CVl 
and NSAID treatments were highly effective and there was no sta- 
tistically significant difference between the two drugs (p=0.909). 
There was, however, a slight advantage in favor of CVI in the esti- 
mate of the magnitude of the effect. Analysis of the activity of 
each treatment compared with the corresponding baseline value 
demonstrated that both CVI and NSAID were very effective treat- 
ments with statistically significant improvements in all primary 
outcome parameters (lameness, pain and orthopaedic score) at 
all weeks (p<0.05). The efficacy of each treatment was also 
demonstrated for secondary outcomes with significant improve- 
ments in gait stiffness and get up and go at all weeks and gait 
